Trial · NCT01074294
Adverse events60
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 60
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | Phase A (Single-blind Prospective Treatment Phase): Placebo + Stimulant | 0 | 733 | |
| other | Diarrhoea | Gastrointestinal disorders | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | 3 | 155 | |
| other | Diarrhoea | Gastrointestinal disorders | Phase B (Double-blind Randomization Phase): Placebo + Stimulant | 5 | 80 | |
| other | Diarrhoea | Gastrointestinal disorders | Phase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant | 0 | 339 | |
| other | Upper respiratory tract infection | Infections and infestations | Phase A (Single-blind Prospective Treatment Phase): Placebo + Stimulant | 0 | 733 | |
| other | Upper respiratory tract infection | Infections and infestations | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | 5 | 155 | |
| other | Upper respiratory tract infection | Infections and infestations | Phase B (Double-blind Randomization Phase): Placebo + Stimulant | 5 | 80 | |
| other | Upper respiratory tract infection | Infections and infestations | Phase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant | 0 | 339 | |
| other | Weight decreased | Investigations | Phase A (Single-blind Prospective Treatment Phase): Placebo + Stimulant | 47 | 733 | |
| other | Weight decreased | Investigations | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | 5 | 155 | |
| other | Weight decreased | Investigations | Phase B (Double-blind Randomization Phase): Placebo + Stimulant | 6 | 80 | |
| other | Weight decreased | Investigations | Phase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant | 0 | 339 | |
| other | Headache | Nervous system disorders | Phase A (Single-blind Prospective Treatment Phase): Placebo + Stimulant | 128 | 733 | |
| other | Headache | Nervous system disorders | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | 11 | 155 | |
| other | Headache | Nervous system disorders | Phase B (Double-blind Randomization Phase): Placebo + Stimulant | 10 | 80 | |
| other | Headache | Nervous system disorders | Phase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant | 0 | 339 | |
| other | Insomnia | Psychiatric disorders | Phase A (Single-blind Prospective Treatment Phase): Placebo + Stimulant | 0 | 733 | |
| other | Insomnia | Psychiatric disorders | Phase B (Double-blind Randomization Phase): Brexpiprazole + Stimulant | 13 | 155 | |
| other | Insomnia | Psychiatric disorders | Phase B (Double-blind Randomization Phase): Placebo + Stimulant | 1 | 80 | |
| other | Insomnia | Psychiatric disorders | Phase A+ (Single-blind Phase A Responders and Non-responders): Placebo + Stimulant | 0 | 339 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01074294/events